Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric AdenocarcinomaPeter Thuss‐Patience, Mascha Binder, Frank Kullmann et al.|JAMA Network Open|2024Cited by 13
Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Peter Thuss‐Patience, Alexander Stein, Anica Högner et al.|Journal of Clinical Oncology|2022Cited by 4
3558 POSTER Metastatic small bowel adenocarcinoma: favourable outcome in patients with primary tumour resected – retrospective analysis of 44 casesAlbrecht Kretzschmar, Jakob Hartmann, M. Stahl et al.|European Journal of Cancer Supplements|2007Cited by 0
Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).Peter Thuss‐Patience, Mascha Binder, Anica Högner et al.|Journal of Clinical Oncology|2023Cited by 0